Skip to main content

Opens in new window

NHS Wales
NHS 111 Wales

Skip Navigation
Accessibility
Contact us
Cymraeg

All Wales Therapeutics and Toxicology Centre

Cymraeg

Home
Accessing medicines
Access to medicines in Wales Medicine recommendations Make a submission
Medicines optimisation and safety
Medicines optimisation guidance, resources and data Yellow Card Centre Wales Welsh National Poisons Unit
Work in progress
News, meetings and events
News Meetings Events
About us
Who we are What we do Our committees Who we work with Our research Our reports and strategies Sustainability Contact us

Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25)
Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24)
Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23)
Dabrafenib and trametinib for anaplastic thyroid cancer (OW27)
Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20)
Bevacizumab for ovarian cancer (OW01)
Bendamustine and rituximab for mantle cell lymphoma (OW09)
Bendamustine and rituximab for indolent lymphomas (OW08)
Rituximab for interstitial lung disease (OW13)
Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19)
Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04)
Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06)
Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16)
Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15)
Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26)
Rituximab for pemphigus and pemphigoid (OW10)
Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18)
Rituximab for myasthenia gravis (OW12) - reassessment
Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22)
Infliximab for the treatment of ICI induced enterocolitis (OW21)
Denosumab (Prolia®) for osteoporosis in men (OW07)

NHS Wales
NHS 111 Wales

Accessibility
Contact us

Home
› Links
› Latest One Wales decisions

Latest One Wales decisions

15/02/2023
Denosumab (Prolia®) for osteoporosis in men (OW07): Last review date: December 2022

1
2

Follow AWTTC:

Accessibility
Terms of use
Freedom of information
Privacy policy
All about Cookies

Built by Digital Health and Care Wales